Increasing screening for breast cancer using a randomized evaluation of electronic health record nudges: Design and rationale of the I-screen clinical trial
Kimberly J. Waddell , Shivan J. Mehta , Joshua M. Liao , Kristin A. Linn , Saehwan Park , Corinne M. Rhodes , Caitlin Brophy , Catherine Reitz , Deborah S. Cousins , Keyirah Williams , Esther J. Thatcher , Ryan Muskin , Peter J. Pronovost , Amol S. Navathe
{"title":"Increasing screening for breast cancer using a randomized evaluation of electronic health record nudges: Design and rationale of the I-screen clinical trial","authors":"Kimberly J. Waddell , Shivan J. Mehta , Joshua M. Liao , Kristin A. Linn , Saehwan Park , Corinne M. Rhodes , Caitlin Brophy , Catherine Reitz , Deborah S. Cousins , Keyirah Williams , Esther J. Thatcher , Ryan Muskin , Peter J. Pronovost , Amol S. Navathe","doi":"10.1016/j.cct.2024.107753","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Routine mammogram screening is critical for early detection of breast cancer. However, screening rates are below national targets, with persistent disparities among sub-populations. The purpose of this trial is to examine the effectiveness of a multi-component nudge intervention to increase breast cancer screening among eligible primary care patients.</div></div><div><h3>Methods</h3><div>This is a two-phase, multisite, pragmatic cluster randomized clinical trial. In the first phase, two concurrent trials (trial A, B) will test the effectiveness of a multi-component nudge intervention that leverages the electronic health record (EHR) for increasing mammogram screening. The second phase includes a replication trial at an additional site. In Trial A, primary care clinics (<em>n</em> = 30) will be randomized 2:1 to a nudge intervention or usual care. Eligible clinicians and patients within the intervention clinics will receive the intervention. Patients identified as high-risk for mammogram non-completion in the intervention arm will be further randomized 1:1 to receive an intensification nudge. In Trial B, primary care clinicians (<em>n</em> = 82) will be randomized 1:1 to a nudge intervention or usual care. The primary outcome is mammogram completion within three months of the eligible visit.</div></div><div><h3>Analysis</h3><div>Outcomes will be evaluated using generalized estimating equations (GEE) to address clinic-level clustering. GEE models will also be fit to evaluate the impact of the intensification nudge on mammogram completion.</div></div><div><h3>Conclusion</h3><div>If successful, this trial provides a blueprint for leveraging scalable multi-component nudge interventions for clinicians and patients to improve cancer screening rates.</div></div>","PeriodicalId":10636,"journal":{"name":"Contemporary clinical trials","volume":"148 ","pages":"Article 107753"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary clinical trials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1551714424003367","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Routine mammogram screening is critical for early detection of breast cancer. However, screening rates are below national targets, with persistent disparities among sub-populations. The purpose of this trial is to examine the effectiveness of a multi-component nudge intervention to increase breast cancer screening among eligible primary care patients.
Methods
This is a two-phase, multisite, pragmatic cluster randomized clinical trial. In the first phase, two concurrent trials (trial A, B) will test the effectiveness of a multi-component nudge intervention that leverages the electronic health record (EHR) for increasing mammogram screening. The second phase includes a replication trial at an additional site. In Trial A, primary care clinics (n = 30) will be randomized 2:1 to a nudge intervention or usual care. Eligible clinicians and patients within the intervention clinics will receive the intervention. Patients identified as high-risk for mammogram non-completion in the intervention arm will be further randomized 1:1 to receive an intensification nudge. In Trial B, primary care clinicians (n = 82) will be randomized 1:1 to a nudge intervention or usual care. The primary outcome is mammogram completion within three months of the eligible visit.
Analysis
Outcomes will be evaluated using generalized estimating equations (GEE) to address clinic-level clustering. GEE models will also be fit to evaluate the impact of the intensification nudge on mammogram completion.
Conclusion
If successful, this trial provides a blueprint for leveraging scalable multi-component nudge interventions for clinicians and patients to improve cancer screening rates.
背景:常规乳房 X 线照相筛查对于早期发现乳腺癌至关重要。然而,筛查率低于国家目标,亚人群之间的差距持续存在。本试验的目的是研究由多部分组成的激励干预措施对提高符合条件的初级保健患者乳腺癌筛查率的有效性:这是一项分两个阶段、多地点、务实的群组随机临床试验。在第一阶段,两项同时进行的试验(试验 A、B)将检验利用电子健康记录(EHR)提高乳房 X 光筛查率的多成分干预措施的有效性。第二阶段包括在另一个地点进行复制试验。在试验 A 中,初级保健诊所(n = 30)将按 2:1 的比例随机接受劝导干预或常规护理。干预诊所内符合条件的临床医生和患者将接受干预。在干预组中被确定为未完成乳房 X 光检查的高风险患者将进一步按 1:1 随机分配接受强化督促。在试验 B 中,初级保健临床医生(n = 82)将以 1:1 的比例随机接受干预或常规护理。主要结果是在符合条件的就诊后三个月内完成乳房 X 光检查:结果将使用广义估计方程(GEE)进行评估,以解决诊所层面的聚类问题。还将拟合 GEE 模型,以评估强化督促对乳房 X 光检查完成率的影响:如果试验成功,它将为临床医生和患者提供一个利用可扩展的多成分劝导干预来提高癌症筛查率的蓝图。
期刊介绍:
Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.